Since NAFLD, diabetes and CKD are complications of the metabolic syndrome, this points to the potential utility of PGC-1α-based therapeutic approaches to target the different complications of metabolic syndrome. Here, PPARGC1A is linked to metabolic dysfunction-associated steatotic liver disease.